Phytopharm Share Discussion Threads

[mrsapeslaptop] 22/6/2011 12:45

Recruitment started in Nov 2010. 28 weeks duration, so perhaps the first recruits have completed. I know full results arent out until end 2012. but if your relative was on the trial you would notice if the drug had actually reversed some of the symptoms.

[mrsapeslaptop] 22/6/2011 12:31

imake it over 1% of the company and all buys.

largest volume in over a year. someone is taking notice

[madmonkflin] 22/6/2011 12:26

weird volumes today?

[mrsapeslaptop] 21/6/2011 23:06

excellent find.

we seem to be a sibgle drug, multiple indication company.
6 months we'll know how may (or none indications). 18 months we'll know if Parkinson P2 successful.

showed someone the cahrt today (10 year). you can lose 99% of your investment, or make 100 times. we'll see.. cheers monk

[madmonkflin] 21/6/2011 22:38

this the pre-clinical human trial for seeing if cogane works on motor neurone disease - trial is for 12 months from Jan 2011

[mrsapeslaptop] 10/6/2011 15:26

this was presented on Monday at the movement disorders conference

Prior treatment with PYM50028, an orally active neurotrophic factor
modulator in development for Parkinson's disease, reduces L-Dopa
induced dyskinesia in MPTP-lesioned macaques
T.H. Johnston, S.H. Fox, P.A. Howson, J.M. Brotchie (Toronto,
Ontario, Canada)

hopefully it will be published/ available to the rest of us soon.

[madmonkflin] 06/6/2011 21:02

whats the gist of the article?

[mrsapeslaptop] 30/5/2011 00:02

wait for the idiots on the news. ridiculous biotech valuations at the mo.

18 months to build a position if you yave the patience

[baldeagle5] 29/5/2011 09:53

I keep looking at below and re-reading it. For the life of me I can't understand why the shares didnt at least double on this statement -

"In a preclinical study, oral administration of CoganeTM over eighteen weeks significantly reduced parkinsonian disability by 43% in the gold standard preclinical model of Parkinson's disease research (MPTP-induced Parkinson's disease model), which we believe will be clinically highly relevant if repeated in Parkinson's disease patients. Encouragingly, in this study a statistically significant reduction in parkinsonian symptoms was reached after nine weeks of administration with CoganeTM. The magnitude of the effect increased over the subsequent nine weeks of administration and was still increasing at the end of the study (week eighteen)."

[mrsapeslaptop] 28/5/2011 13:18

just had a brainwave.

where did Cogane reducing the side effects of L Dopa come from that was mentioned in the results??

I'm not aware of this ever being mentioned before.

Is it an observation from the current clinical trials ? In which case it may not be as blind as stated. i.e. you can observe whose on Cogane because they have fewer side effects from the L Dopa.

[algernon2] 28/5/2011 00:44

interesting, Cogane to reduce side effects of L-Dopa till the point L Dopa ceases to have any further effect;then switch to Prosavin from Oxford Biomedica (OXB) for the gene therapy to use the 3 genes to recreate a new dopamine factory in the sufferers striatum.
Synergistic and potential winner(s),
Or an idle pipe dream?
Time will tell but after half a bottle of Madeira at 1.42 in the morning I see no flaws in this plan and a lot of upside to it.
Your thoughts gentlemen.

[mrsapeslaptop] 27/5/2011 09:49

so my take on results.

- we could move to PII trials in ALS & Glaucoma before the end of the year.
which would potentially give us 3 drugs in P2

- Alzheimers may be revived once there is funding available

- looking at Cogane as a side effect moderating drug for L-dopa treatment (which massively de risks the Parkinsons trial. even if parkinsons trial doesnt reach its primary endpoint. the market could be just as large if it reduces side effects of existing treatments)

[msape] 27/5/2011 01:21

long term chart.

I shorted this fron 600p.

If I get the long as well. the image isnt worth shareing

[baldeagle5] 26/5/2011 15:54

Ape/mad monk - IF it works and goes into production/partnership with a major pharmo then 60p would indeed be cheap.

[madmonkflin] 26/5/2011 15:26

the good thing is theres no bad news. yet. I bloody hope there isn't.
60p would be cheap if it was working.

[mrsapeslaptop] 26/5/2011 14:27

considering we are well into P2 and fully funded. we could get 60p by year end imho

[nick rubens] 26/5/2011 13:26

Is PYM getting Jiggy? A couple of 100,000 buys has ticked it up.

[baldeagle5] 26/5/2011 13:13

Good an encouraging early results re Cogane in this mornings result.
Still at floor 1 in the elevator here...

[msape] 22/5/2011 12:19

this one seems to have gartmore buying dribbles every month. but otherwise very little buying or selling. and its ISAable.

but yes. SUMM should be 60p able

[moneymunch] 21/5/2011 22:27

i wandered lonely as a cloud!!! you dirty b'stard, let me know when the next beer/perry festival is and i might join you.LOL ;-)
ps i might have a look here when Summ comes in, in the meantime i'm going to start to look hard for the next big thing....i'm drawn to Trp, plenty of upside until they don't find any oil, and i find Asm intruiging, it looks dead and buried, but a major shareholder is accumulating more???? We're on to another serious winner with Summ....Let the good times roll!!! ;0)))

[msape] 21/5/2011 10:02

results on Thursday.

[mrsapeslaptop] 18/5/2011 17:24

we should be getting news on at least one of these in the next few months

Encouraging early data from the recently initiated programme investigating the effect of Cogane™ and Myogane™ in glaucoma

Initiation of "gold standard" in-vivo model investigating the effect of Cogane™ in Amyotrophic Lateral Sclerosis (ALS) with the support of the Motor Neurone Disease Association

Re-activation of P61 anti-inflammatory project